Thyme Care Raises $125M and Builds Thyme Companies

Thyme Care raised more than $125M in Series E funding on September 2, 2026, at a valuation above $2B. Morgan Health led the round, with Humana, CVS Health Ventures, AlleyCorp, HealthQuest Capital, Foresite Capital, Concord Health Partners, Frist Cressey Ventures, Town Hall Ventures, and a16z Bio + Health participating.

The Nashville oncology company also established Thyme Companies, a new parent organization designed to build independent businesses around persistent gaps in cancer care. Co-founder Robin Shah will serve as executive chairman of Thyme Companies. Brad Diephuis remains CEO of Thyme Care, working alongside co-founder, President, and Chief Medical Officer Bobby Green, MD.

The financing is larger than a runway extension. Thyme Care is using a care-navigation business built between patients, oncology practices, health plans, and employers as the operating base for a broader portfolio. Initial areas under development include accelerating lower-cost biosimilar adoption and improving clinical-trial accrual. The first new business is expected to launch later in 2026.

What Thyme Care Announced

The official Series E announcement lists Morgan Health as lead investor and names Humana and CVS Health Ventures as strategic healthcare participants. AlleyCorp, HealthQuest Capital, Foresite Capital, Concord Health Partners, Frist Cressey Ventures, Town Hall Ventures, and a16z Bio + Health also joined the financing.

The company described the round as more than $125M and the valuation as more than $2B. Individual check sizes, ownership percentages, and detailed transaction terms were not disclosed. Thyme Care's September 2025 Series D announcement said the company had raised $275M through that round, so the Series E puts disclosed cumulative capital above $400M, although the latest release did not publish a new lifetime total.

Thyme Care was founded in 2020 by Robin Shah and Bobby Green. The company is headquartered in Nashville and operates a technology-enabled oncology navigation and value-based care model. It works with health plans, employers, risk-bearing providers, and oncology practices while providing patients with clinical and non-clinical support between visits.

Why Strategic Investors Matter Here

This financing syndicate resembles the system Thyme Care must coordinate. Morgan Health focuses on employer-sponsored healthcare. Humana and CVS Health operate across insurance, care delivery, and consumer health. The other investors bring healthcare, venture, and growth capital perspectives.

That composition matters because Thyme Care's economics depend on several institutions agreeing that earlier support, better coordination, and lower-cost clinical choices create shared value. A patient experiences cancer as one continuous journey. The payment and delivery system divides that journey among plans, practices, pharmacies, employers, and hospitals. Thyme Care is paid to make those handoffs less expensive and less punishing.

Humana's CenterWell partnership with Thyme Care shows the model in practice. Eligible patients receive 24/7 access to an oncology-trained virtual team, help coordinating appointments and symptoms, connections to local resources, and collaboration with primary-care and oncology teams. The commercial proposition is that proactive intervention can improve the experience while avoiding preventable acute care.

Thyme Care's Reported Scale and Outcomes

Thyme Care says its services are available to more than 10.5M people across all 50 states and that it manages more than $7B in oncology spend. The company reports 5% to 10% validated reductions in total cost of care, profitability, and positive free cash flow.

Fierce Healthcare reported that Thyme Care served 135,000 actively treated cancer patients as of August 2026, up from 10,000 at the end of 2024. Fierce also reported that the company's care team integrates with more than 1,400 oncologists. These figures describe meaningful operating scale, but they remain company-reported metrics rather than independently audited public-company disclosures.

The current numbers build on evidence reported with the 2025 Series D. Thyme Care then said it had access to 8M people, managed more than $5B in oncology spend, and worked with more than 1,000 oncologists. The direction is clear: more covered lives, more spend under management, and a larger provider network. The harder question is whether outcomes and cost reductions remain consistent across that growth.

From Thyme Care to Thyme Companies

The new parent structure changes the scope of the business. Thyme Care focuses on navigation, continuous support, data, and value-based oncology relationships. Thyme Companies is intended to create separate businesses that address problems encountered through that network.

The first two areas reveal where the parent sees leverage. Biosimilars can reduce the cost of biologic cancer medicines, but adoption depends on clinical confidence, purchasing arrangements, reimbursement, patient access, and provider incentives. Clinical trials face a different coordination failure: eligible patients, treating oncologists, research sites, sponsors, and data systems often do not connect quickly enough.

Those are adjacent to navigation, but they are not merely navigation features. Each could require different products, operating teams, regulatory approaches, commercial relationships, and capital. Thyme Companies therefore represents a portfolio thesis: use the data, trust, distribution, and accountability relationships built by Thyme Care to launch focused businesses against other oncology bottlenecks.

Leadership for the Next Phase

Robin Shah moved from Thyme Care CEO to executive chairman in July 2026. Thyme Care's leadership profile describes Brad Diephuis as a primary-care physician and cancer survivor who previously served as president and COO. Diephuis now leads the core company while Shah concentrates on new business creation.

The current Thyme Care team page lists Bobby Green, MD, as co-founder, President, and Chief Medical Officer. Green is a medical oncologist whose clinical and operating experience has shaped the company's provider-facing model. The division of roles gives Thyme Companies a founder focused on portfolio formation while keeping physician leadership around the scaled navigation business.

What the $125M Must Prove

Thyme Care has reached a point where capital, strategic distribution, and operating results reinforce one another. Its backers include organizations that can help place the service inside more benefit designs, provider relationships, and care pathways. Profitability and positive free cash flow, if sustained, give the parent more freedom to build or acquire businesses without treating each experiment as a separate survival event.

The risks are equally structural. A portfolio can pursue several oncology problems, but it can also recreate the fragmentation it was designed to reduce. Cost-savings claims must remain credible across populations and contracts. Biosimilar initiatives have to navigate incentives that do not always reward the lowest-cost clinical option. Trial-access products have to improve matching and enrollment without adding another workflow burden for practices.

Thyme Care made the space between appointments visible to investors and buyers. Thyme Companies now plans to move upstream into drug economics and clinical research. The useful question is whether one connected view of the cancer journey can produce several focused businesses while leaving patients with fewer handoffs, not a larger corporate family they must learn to navigate.